Business
Nemaura Medical Inc. Announces Uplist to OTCQB
Nemaura Medical Inc. Announces Uplist to OTCQB.
About this update from Nemaura Medical, Inc.
[{"type":"text","content":"\n \n Nemaura Medical Inc. (OTC: NMRD), a medical technology company focused \n on the development and commercialization of sugarBEAT®, a wireless \n disposable adhesive skin-patch for adjunctive use by diabetics as a \n non-invasive and needle-free continuous glucose monitoring (CGM) system \n announced it has recently uplisted to the OTCQB Venture Market trading \n platform.\n \n \n Dr Faz Chowdhury, CEO of Nemaura Medical commented \"We are pleased to \n announce our uplist to the OTC Quote Board, which we expect will enhance \n our visibility in the marketplace, broaden and diversify our investor \n base, and increase the liquidity of our common stock.\"\n \n \n About Nemaura Medical, Inc.\n \n \n Nemaura Medical is a medical technology company developing the wireless \n sugarBEAT® disposable adhesive skin-patch as a non-invasive, \n needle-free, pain-free and affordable continuous glucose monitoring \n (CGM) system for adjunctive use by diabetics. For more information, \n please visit www.nemauramedical.com.\n \n \n Cautionary Statement Regarding Forward Looking Statements\n \n \n The statements in this press release that are not historical facts, and \n may constitute forward-looking statements that are based on current \n expectations and are subject to risks and uncertainties that could cause \n actual future results to differ materially from those expressed or \n implied by such statements. Those risks and uncertainties include, but \n are not limited to, risks related to regulatory approvals and the \n success of Nemaura Medical’s ongoing studies, including the safety and \n efficacy of Nemaura Medical’s sugarBEAT® CGM system, the failure of \n future development and preliminary marketing efforts, Nemaura Medical’s \n ability to secure additional commercial partnering arrangements, risks \n and uncertainties relating to Nemaura Medical and its partners’ ability \n to develop, market and sell sugarBEAT®, the availability of substantial \n additional equity or debt capital to support its research, development \n and product commercialization activities, and the success of its \n research, development, regulatory approval, marketing and distribution \n plans and strategies, including those plans and strategies related to \n sugarBEAT®. These and other risks and un...